fda on compounded tirzepatide decision Says Must Exit the Market FDA Allows Compounded Tirzepatide During – FDA ban on compounded tirzepatide:

It acts from a lack of equilibrium between two neurotransmitters in the basal ganglia: dopamine (inhibitory) and acetylcholine (excitatory)

The distinction matters because compounded medications are not FDA-approved, meaning no regulatory body has reviewed these specific formulations for safety, efficacy, or quality

Understanding that headaches are a known potential side effect can help patients and healthcare providers anticipate and manage this reaction appropriately

One feature distinguishes this format from buying the two components separately: each vial holds half the peptide loading of a standalone single-compound vial